Trial of Diet, Physical Activity and Breast Cancer Recurrences: the DIANA-5 Study
NCT05019989 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1542
Last updated 2021-08-25
Summary
The investigators recruited 1542 Breast Cancer (BC) patients and to randomize the participants in two groups: 773 have received standard recommendations for healthy lifestyle without, however, any active support; 700 have received a combination of individual and group contacts over the course of one year, including kitchen courses, gym and dance classes, common meals and reinforcing meetings, with emphasis on a comprehensive dietary change including low saturated fat and low refined carbohydrates, and high whole grain cereals and pulses consumption. Compliance have been monitored through weight change and plasma glucose, triglycerides, cholesterol and testosterone.
The main analysis will be by intention to treat. Under the hypothesis of reducing recurrence rate by 25% or 33% the statistical power of the study is 80% or, respectively, 90%, (P\<0.05, 5-year follow-up).
Conditions
- Breast Cancer Invasive
Interventions
- BEHAVIORAL
-
Intervention group on diet and physical activity
The intervention wanted to increase physical activity, controlling weight, promoting healthy diet. 1. Physical activity: achieve and maintain regular participation in a moderate intensity physical activity program of 210 minutes/week (30 min on average per day) over at least 3 days /week; decrease sedentary behaviors by 30 minutes/day on at least 5 days/week 2. Weight control: reducing energy intake relative to expenditure is the primary dietary focus for promoting weight loss in overweight or obese participants, and maintaining a healthy energy balance is the primary focus for normal weight participants. Participants will be encouraged to include whole grains and high-fiber vegetables 3. Healthy diet: reducing calorie intake, through the preferred consumptions of unrefined cereals, pulses and vegetables, reducing high glycemic index food and high insulinemic foods, such as sugar and milk; reducing sources of saturated fat and animal protein (except fish)
- BEHAVIORAL
-
Control group: only public recommendation an lifestyle
1. Invitation leaflet, explaining the rationale of the study and including basic life-style recommendations, based on the 1997 World Cancer Research Fund recommendations (to be updated in 2007) and the Italian National Institute of Nutrition food pyramid. 2. Dissemination of the information on the study by media 3. Yearly follow-up questionnaire on breast events and dietary and physical activity chang
Sponsors & Collaborators
-
Associazione Italiana per la Ricerca sul Cancro
collaborator OTHER -
European Institute of Oncology
collaborator OTHER -
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte
collaborator OTHER -
Federico II University
collaborator OTHER -
IRCCS Cancer Referral Center of Basilicata
collaborator OTHER -
ARNAS Civico Di Cristina Benfratelli Hospital
collaborator OTHER -
Lega Italiana per la Lotta contro i Tumori
collaborator OTHER -
Azienda Socio Sanitaria Territoriale di Mantova
collaborator OTHER -
Ministero della Salute, Italy
collaborator OTHER -
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
lead OTHER
Principal Investigators
-
ANNA VILLARINI, PhD · Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 35 Years
- Max Age
- 70 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-06-01
- Primary Completion
- 2012-09-30
- Completion
- 2017-09-30
More Related Trials
-
A Study to Learn About the Safety of TALZENNA for the Treatment of Breast Cancer
NCT06735742 ·Status: ACTIVE_NOT_RECRUITING
-
Feasibility of Lifestyle Intervention in BRCA1/2 Mutation Carriers
NCT02087592 ·Status: COMPLETED ·Phase: NA
-
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
NCT05262400 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Supervised Physical Activity in Young Women With Early Breast Cancer During Neoadjuvant Chemotherpy
NCT06190600 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer
NCT04001829 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast Cancer
NCT00309920 ·Status: UNKNOWN ·Phase: NA
-
Gene Expression Profiling and Genetic Analysis of Tissues From Patients With Breast Cancer
NCT00899509 ·Status: COMPLETED
-
Docetaxel Plus Garlic in Treating Patients With Locally Advanced or Metastatic Breast Cancer
NCT00079170 ·Status: COMPLETED ·Phase: NA
-
A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment
NCT01301729 ·Status: COMPLETED ·Phase: PHASE4
-
Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer
NCT01928589 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer
NCT00003095 ·Status: COMPLETED
-
Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)
NCT01976169 ·Status: COMPLETED ·Phase: PHASE1
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
NCT05020860 ·Status: RECRUITING ·Phase: PHASE2
-
Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast
NCT00470236 ·Status: UNKNOWN ·Phase: NA
-
Studying Biological Markers of Fatigue in Women With Residual Invasive Breast Cancer Enrolled on Clinical Trial NSABP-B-45
NCT00914043 ·Status: WITHDRAWN
-
A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel
NCT00131963 ·Status: COMPLETED
-
Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer
NCT00005800 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer
NCT03939481 ·Status: ACTIVE_NOT_RECRUITING
-
A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer
NCT00567190 ·Status: COMPLETED ·Phase: PHASE3
-
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
NCT00079118 ·Status: COMPLETED ·Phase: PHASE2
-
Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer
NCT00925652 ·Status: TERMINATED ·Phase: PHASE2
-
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer
NCT00003972 ·Status: COMPLETED ·Phase: PHASE3
-
Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer
NCT02909751 ·Status: COMPLETED ·Phase: PHASE2
-
Dose Dense TC + Pegfilgrastim Support for Breast Cancer
NCT01671319 ·Status: COMPLETED ·Phase: PHASE2
-
Survival TRaining for ENhancing Total Health (STRENGTH)
NCT00068458 ·Status: COMPLETED ·Phase: PHASE2